More transparency of pharmaceutical prices: 

The EURIPID project 

STAMP meeting 
08. 12. 2017 Brussels 
Gergely Németh 
(project manager)
"The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains."
1.1 What is the EURIPID undertaking?

- A voluntary non-profit COLLABORATION of the European P&R authorities for the mutual sharing of price information of medicinal products

- A TECHNICAL TOOL to make prices of pharmaceuticals more transparent in Europe

- An attempt to create a comprehensive, continuously maintained, easy-to-use online DATABASE of prices of reimbursed pharmaceuticals
1.2 History

- **CEDD pilot project**
- **EURIPID project**
- **DG ENTR, OEP, GÖG/ÖBIG**
- **EURIPID Collaboration**
- **national P&R authorities**
- **EURIPID Collaboration & DG SANTE grant**
- **national P&R authorities**
- **Cooperation with EUROSTAT**

- **2008-2010**
- **2010-2013**
- **2014-2015**
- **2015-2018**
- **2017**
1.3 The EURIPID Collaboration

**Legal issues**
- Framework Partnership Agreement
- General Terms and Conditions
- Terms and Conditions of Use of the Website

**Organisation**
- Founders, Partners, Associated Partners, European Commission
- Board of Participants (BoP) (one delegate per country + EC)
- Executive Committee (3 delegates of the BoP + OEP + GÖG/ÖBIG + EC repr.)
- project team (OEP & GÖG/ÖBIG)

**Finances**
- non-profit
- annual contribution fee equally shared
- the budget depends on the number of participants
1.4 Status of recruitment

**Participating countries in 2017:**

Austria  
Belgium  
Bulgaria  
Croatia  
Czech Republic  
Cyprus  
Denmark  
Estonia  
Finland  
France  
Greece  
Hungary  
Ireland  
Israel  
Italy  
Latvia  
Lithuania  
Netherlands  
Norway  
Poland  
Portugal  
Slovakia  
Slovenia  
Spain  
Sweden  
Switzerland  
United Kingdom

*Not participants but data available:* Iceland

*Former participant:* Albania, Romania
1.5 Operational model

Information provision by the national authorities
- Only publicly available information

Data standardisation by the project team
- In line with the data standardisation manual

Easy to use web platform
- Standard structure
- Relevant clustering of products
1.6 Information content

Data content

- Product code
- Product name
- Package
- Prices
- Company

ATC
Dosage form
Route of admin.
INN & strengths
No of units

Manufacturer price*
Wholesale price*
Net retail price*
Gross retail price*

- Manufacturer price/unit
- Wholesale price/unit
- Net retail price/unit
- Gross retail price/unit

* Converted to another currency

data provided by the authorities

data standardised by the project team

calculated fields
2.1 SWOT analysis of the EURIPID Collaboration

**Strengths**
- 8 years of experience
- Successful operational model
- Most EU Member States are participants

**Weaknesses**
- Limited in scope
- Only official prices
- Access is restricted

**Opportunities**
- Bringing together the experts on pricing
- Extension of the dataset
- Cooperation with other databases/projects (e.g. EMVS)
- Geographic extension of the collaboration

**Threats**
- Confidential pricing
36. Notes that the EURIPID project needs more transparency from Members States to include the real prices paid by them;

2.3 Reply of EURIPID to the call of the EP

- Limited and step-wise increase of transparency within the EU
- Voluntary cooperation between the Member States and pharma companies
- No price distortion mechanisms for the concerned products in any MS
- The principles of ERP and price differentiation (if any) shall be laid down
- EURIPID could be of large value in such a procedure
3.1 Reasons of access restrictions

- Preventing free riding
- Data ownership issues
- Concerns about parallel trade
- Concerns about the misinterpretation of prices (sales volumes, pricing structures matters, real prices vs. list prices)
- Incalculable effect on pricing and access to medicines on a global level
- The stakeholders have not yet expressed their explicit interest for accessing the EURIPID website
## 4.1 DG SANTE grant objectives

To achieve a better coordination at the EU level in order to facilitate the control by the Member States of public budgets for medicinal products whilst avoiding/mitigating possible negative impacts on patient access to medicinal care.

<table>
<thead>
<tr>
<th>SO.1</th>
<th>SO.2</th>
<th>SO.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determining an optimised dataset and data lay-out (in collaboration with the stakeholders)</td>
<td>Providing the necessary (additional) information</td>
<td>Developing a Guidance Document on external reference pricing (in collaboration with the stakeholders)</td>
</tr>
</tbody>
</table>
4.2 Facing the future

Development of the EURIPID website (under the EU grant):
- Information on the existence of managed entry agreements
- Information on sales volumes

Development of a technical Guidance Document on external reference pricing (under the EU grant)

Cooperation with other initiatives:
- EMA article 57 database
- EMVS (European Medicines Verification System)
- EUROSTAT

Post-grant period
- Implementation of the recommendations of the Guidance Document
- Training of users
THANKS FOR YOUR ATTENTION!
nemeth.ger@neak.gov.hu